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The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) concept of certainty of
evidence (also called quality of evidence) represents our
confidence that the true effect lies above or below a
threshold, or in a specified range [1]. To assess the certainty
of evidence for an individual outcome, authors of system-
atic reviews, health technology assessments (HTAs), or
guidelines need to specify the thresholds or ranges they
are using and the associated rationale. Several approaches
exist for setting thresholds and ranges. For recommenda-
tions in clinical practice and public health guidelines,
GRADE has suggested setting a threshold based on consid-
eration of all critical outcomes. For systematic review au-
thors, we have illustrated three different approaches:
expressing certainty in the range set by the 95% confidence
interval (CI), certainty in the direction of effect, or certainty
in a particular magnitude of effect, for example, small, me-
dium, or large.
Although GRADE has illustrated the concept of cer-
tainty using effects of treatment interventions, the guidance
to specify ranges or thresholds also applies to questions of
diagnostic tests. When diagnostic intervention studies
comparing alternative diagnostic test strategies with direct
assessment of patient-important outcomes are available
(such as RCTs addressing the impact on survival after a
screening strategy), the approaches for setting thresholds
or ranges previously presented apply [1]. In this paper,
we will explore the concepts when there are no such
studies.
If no studies have directly compared the effects of alter-
native test strategies on downstream health outcomes,
modeling the impact of diagnostic accuracy on the health
outcomes could inform management decisions [2,3]. For
example, false-negative (FN) and false-positive (FP) test re-
sults, by missing or delaying the diagnosis (FN) or through
unnecessary treatment (FP), can adversely impact health
outcomes [2,3]. GRADE previously described that to eval-
uate impact, one may, through formal or informal
modeling, link different types of evidence: diagnostic test
accuracy estimates (e.g., sensitivity and specificity), direct
effects of the test(s) (e.g., complications of an invasive test),natural course of the condition, treatment effectiveness, and
the link between the test results and clinical management
[2e4]. Arriving at an overall rating of certainty of evidence
requires rating every component.
This article explores possible ways of setting thresholds
or ranges for rating certainty in diagnostic test accuracy,
and what this would mean in the context of systematic re-
views, HTA, and health care recommendations. GRADE
has described approaches for setting thresholds or ranges
in terms of levels of contextualization [1]. Box 1 presents
levels of contextualization for diagnostic accuracy, con-
cepts that this paper will further illustrate. The discussion
is consistent with previous guidance on rating certainty in
diagnostic accuracy [2e4].2. Definitions and scope
In our previous work clarifying the construct of certainty
of evidence, we used the term threshold as a set border
(e.g., a threshold at which the benefits start outweighing
the harms) and the term range when using two borders
(e.g., the upper and lower limits of a small effect).
Although one could use the same terminology for the bor-
ders set in test accuracy, to avoid confusion with the thresh-
olds used to dichotomize the test results for a particular test,
throughout this paper, we will use range meaning threshold
or range.
We use the term test strategy to denote a combination of
tests (e.g., clinical test followed by magnetic resonance im-
aging), not to be confused with test-treatment strategy that
also includes the treatment that is guided by the test result
[2]. The test under consideration can have different roles
within a test strategy: to replace an existing test, as triage
test before an existing test, as an add-on to an existing test
[5], or parallel to an existing test [6]. When evaluating diag-
nostic accuracy of a test, it is important to define the role of
the test to address the accuracy of the full test strategy. The
approaches for setting ranges suggested in this paper apply
to all types of test strategies. We will present the ap-
proaches for comparisons between tests as well as for sin-
gle tests, but our main focus will be on the comparative
scenario, which we will further explain below.
Box 1 Degree of contextualization when defining
range
 Noncontextualized (primarily for systematic re-
views and health technology assessments). The
ranges used are independent of value judgments
regarding, for example, the relative importance of
false negatives vs. false positives.
 Partially contextualized (primarily for systematic
reviews and health technology assessments). The
ranges depend on some value judgmentdfor
example, the importance of downstream health
consequences of true and false positives and nega-
tives. This approach to contextualization requires
setting boundaries of ranges expressed in absolute
terms for a given prevalence.
 Fully contextualized (primarily for guidelines and
other decision making). The boundaries are set
considering the range of possible effects on all crit-
ical outcomes, bearing in mind the decision(s) that
need to be made and the associated values and
preferences. This approach to contextualization re-
quires setting boundaries of ranges expressed in
absolute terms for a given prevalence.
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Key findings
 This Grading of Recommendations Assessment,
Development and Evaluation (GRADE) concept
paper shows that the choice of ranges is important
when rating the certainty of evidence for test accu-
racy because it may affect the interpretation of the
result and the degree of certainty presented.
 We present possible approaches for setting ranges
for sensitivity and specificity for a single test and
for a comparison of test options. The approaches
are illustrated using an example of a direct compar-
ison between two test strategies.
What this adds to what was known?
 The GRADE Working Group has previously clari-
fied that the concept of certainty of evidence repre-
sents our confidence that the true effect lies above
or below a threshold, or in a specified range. The
frequent lack of direct evidence assessing the effect
of medical tests on patient important outcomes
highlights the need for a clarification of how these
concepts apply to certainty ratings of test accuracy.
What is the implication and what should change
now?
 When rating the certainty of evidence for test accu-
racy, it is important that systematic review authors,
health technology assessors, and guideline devel-
opers are transparent with the ranges they are us-
ing, the rational for choosing them and with the
value judgments made.
 More empirical data are needed before knowing
which approaches, for defining ranges of accuracy,
would be most useful for different purposes, and
how to best operationalize them.
When addressing the certainty of evidence for test accu-
racy, we are presenting and rating ranges for sensitivity and
specificity. However, when interpreting a test result in clin-
ical practice, multilevel likelihood ratios or multivariable
approaches may be more useful.
We refer to noncontextualized certainty ratings if au-
thors make choices of ranges without value judgments that
do not involve modeling. The term fully contextualized re-
fers to situations in which the entire health care question/
context is considered when assessing the certainty of sensi-
tivity and specificity, typically in the setting of a guideline
[1]. Less-contextualized ratings are typically made in
systematic reviews and HTA. We will continue to make
distinctions between certainty ratings that are fullycontextualized (considering all critical outcomes with their
associated values within a particular decisional context),
partly contextualized (including some value judgment
regarding the importance of the individual outcome), and
noncontextualized (without value judgments). Noncontex-
tualized or partially contextualized approaches refer only
to the chosen ranges and not to other decisions. For
instance, authors of systematic reviews always need to
consider the context of interest, for example, in their eligi-
bility criteria (e.g., only including studies with a certain
prevalence or setting), or when assessing indirectness.
Currently, authors use decision models of varying
complexity to inform decisions regarding test strategies:
ranging from back of the envelope estimations of the possible
consequences to advancedmodels estimating all benefits and
harms to the patients as well as the uncertainty associated
with the parameters in the model [3]. We will exemplify
the contextualized approaches using a simple model esti-
mating the consequences of changes in the sensitivity and
specificity of the test strategies. However, the concepts we
present apply to any level of modeling, requiring
only consideration of all critical direct and downstream
outcomes.3. Comparisons of test strategies
If the goal is to evaluate two test strategies, one can
compare the accuracy of the two tests using a study design
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comparing to the same reference standard (direct compari-
son) [7]. In many cases, however, primary research has only
studied the accuracy of single tests against a reference stan-
dard in separate populations and separate studies. In these
cases, the comparison between the relevant tests will be in-
direct, leading to additional challenges beyond the scope of
this paper.
Table 1 shows possible approaches for setting ranges in
sensitivity and specificity and illustrates what the certainty
ratings represent for a direct comparison vs. a single test.
We will start by presenting an overview of the suggested
approaches and then continue with an example of applying
the approaches to a direct comparison.Table 1. Possible ways of setting ranges for sensitivity and specificity and wha
vs. single test
Degree of contextualization Range How it is
Noncontextualized
(primarily for
systematic reviews and
health technology
assessment)
Range: 95% Confidence
Interval
Using existing l
the 95% CIs,
implies precis
routinely part
rating
Difference s 0 Using the thresh
null effect
Partially contextualized
(primarily for
systematic reviews and
health technology
assessment)
Specified magnitude (set
in natural frequencies
for a given prevalence)
For example, a
difference in
or specificity
defined as a d
small enough
might conside
using the test
effects or cos
appreciable
Fully contextualized
(primarily for
guidelines)
Range determined with
considerations of all
critical direct and
downstream health
outcomes or all
desirable and
undesirable
consequences (set in
natural frequencies for
a given prevalence)
Considering the
possible effec
critical health
outcomes and
consequences
bearing in mi
decision(s) th
be made, and
associated va
preferences
a This will have to be specific to the test, condition, and setting. Sensitiv
test/setting, whereas it may be considered low accuracy for a different scena
sequences based on the test results.
b By certainty range, we mean the range in which we anticipate that th
cision but also risk of bias, inconsistency, indirectness, and publication bia4. Noncontextualized ratings of test accuracy
(typically for systematic reviews and health
technology assessments)
We refer to the first two approaches presented in Table 1
as noncontextualized, meaning that the choice of the
boundaries for the range of sensitivity and specificity does
not involve value judgments (Box 1). That is, the impor-
tance of the number of FNs or FPs does not bear on the
ranges chosen, and the downstream consequences of the
test results have no influence on the certainty ratings of
sensitivity and specificity. Analysts use these approaches
when they wish to assess the certainty of the test accuracy
without further interpreting the results or providing advice.t the certainty expressed will represent for a comparison between tests
set
What the certainty rating represents
For a comparison between
tests For a single test
imits of
which
ion is not
of the
Certainty that the true
difference in accuracy
lies within the
confidence region of
the tests compared or
the true difference in
sensitivity and
specificity lies within
their respective
confidence intervals
Certainty that the true
sensitivity and
specificity lies within
their respective
confidence intervals
old of Certainty that the
sensitivity or specificity
of one test strategy
differs from that of
another
Not applicable
small
sensitivity
can be
ifference
that one
r not
if adverse
ts are
Certainty in a specified
magnitude of
difference between the
sensitivity or specificity
of two tests (e.g., no or
trivial, small, medium,
or large difference)
Certainty in a specified
magnitude of sensitivity
or specificity (e.g., low,
moderate, or high
accuracy)a
range of
ts on all
[3],
nd the
at need to
the
lues and
For each outcome (in this
case sensitivity and
specificity), ratings
represent our
confidence that the
overall balance
between net benefit
and net harm will not
differ from one end of
the certainty rangeb to
the other.
For each outcome (in this
case sensitivity and
specificity), ratings
represent our
confidence that the
overall balance
between net benefit
and net harm will not
differ from one end of
the certainty rangeb to
the other.
ity of 97% may be considered extremely accurate for some conditions/
rio. This decision will be informed by the patient and population con-
e true sensitivity or specificity may lie, after considering not only pre-
s [1,8].
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The first approach assesses how certainwe are that the true
sensitivity and specificity lies within the observed CIs. Using
this approach, one omits the rating of imprecision, that is, one
could have high certainty that the true sensitivity or specificity
lies within the range set by the CI regardless of whether this
range is wide or narrow. The ranges can be presented for
sensitivity and specificity, or for the number of FPs and
FNs, given a particular pretest probability. In comparing
two tests, onewill rate the certainty of the difference in sensi-
tivity and specificity or FPs and FNs between the tests under
consideration. This approach could potentially mean that we
express high certainty in very imprecise results.
4.2. Using the direction of effect
The second approach assesses our certainty regarding
whether a difference exists between the accuracy of two
test strategies. In other words, how certain are we that test
A has a higher/lower sensitivity or specificity than test B?
In some cases, one would want to address the certainty that
the true difference in test accuracy lies close to no differ-
ence. This requires a decision regarding what difference
would be trivial and thus requires a partly contextualized
judgment that we describe in the following.5. Partly contextualized ratings of certainty: ranges of
magnitude of accuracy (typically for systematic re-
views and health technology assessments)
The third option described in Table 1 is to rate our cer-
tainty in a specific accuracy. When applying this approach
to a comparison between two tests, one could specify cate-
gories of no or trivial, small, moderate, or large difference
in accuracy. Similarly, when evaluating the accuracy of a
single test in comparison to the reference standard, one
could specify trivial, low, moderate, or high accuracy. This
approach requires setting boundaries of ranges expressed in
absolute terms for a given prevalenceeboundaries that
likely will depend on the value placed on the direct effects
(i.e., burdens/adverse effects) of the test as well as the
downstream health consequences of the true and false pos-
itives and negatives.
For example, consider a situation in which the down-
stream health consequences of a management decision
are serious, such as recurrence of disease. In such situa-
tions, ranges of FPs and FNs will have a lower value than
if the downstream consequences are less serious such as mi-
nor adverse events or length of hospital stay.6. Fully contextualized ratings (typically for
guidelines) of test accuracy
When we make fully contextualized ratings, we are
simultaneously weighing the benefits and harms of everycritical or important health outcome or even all desirable
and undesirable consequences [1] (Box 1). In the absence
of studies comparing the health consequences of tests,
one would ideally use a fully developed model for assessing
the effects of the test strategies on patient important out-
comes. If such models can generate estimated effects with
CIs, one can make fully contextualized ratings of the pa-
tient important outcomes in the same way as we have pre-
viously described [1]. The accuracy data would in this case
be one of several pieces of data feeding into the model.
Currently, guideline panels seldom have access to
advanced models. As a result, they will inevitably focus
on diagnostic accuracy [9e11]. Here, we discuss how one
can, in these cases, make fully contextualized ratings of
sensitivity and specificity, that is, address whether one
would make a different decision at either end of the cer-
tainty ranges. One can then use models or explicit consid-
erations to decide what sensitivity and specificity one
would require to recommend a particular test. That is, what
levels of sensitivity and specificity would be required to
ensure that the desirable health effects will outweigh the
undesirable. In some cases, it is also possible to set ranges
for sensitivity and specificity by inferring decision thresh-
olds from other recommendations and decisions about
testing [12].
When all else is judged exactly equal between the two
test strategies (e.g., side effects, invasiveness, resources
considerations, timing of test, location of test in the care
pathway, feasibility, availability), the fully contextualized
range would be the same as the noncontextual no-effect
range. Although it is unlikely to occur, one could then base
a decision solely on knowledge of whether the test accuracy
increases or decreases with one test-strategy compared with
another [9,13,14].
Fully contextualized ranges are often decided on through
discussions in guideline panels, based on what is known
about the direct and downstream health outcomes of the test
strategies. In some cases, panels conduct formal surveys of
their members to establish test and treatment thresholds
[15]. In some situations, considering downstream health
outcomes can be sufficient and no formal modeling is
neededdfor example, if it is obvious that the health conse-
quences of using the test would be negative.
In this paper we will illustrate how simple models of
health outcomes can inform the choice of fully contextual-
ized ranges for sensitivity and specificity. If the values are
very uncertain, or the results will be used in several
different contexts, one can provide several certainty ratings,
each for a specific set of values.7. Applying ranges to direct comparisons of accuracy
between test strategies
To make decisions about tests, direct comparisons of the
relevant test strategies are ideal. We will show what the
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using the direct comparison of accuracy between two tests
for cervical cancer screening, the human papillomavirus
(HPV) test (HPV DNA-PCR testing) and unaided visual in-
spection of the cervix with acetic acid (VIA) [16].
Cervical intraepithelial neoplasia (CIN) is a premalig-
nant lesion diagnosed by histology, in three stages: CIN
1, CIN 2, and CIN 3. If left untreated, CIN 2 or 3 (CIN
2-3) can progress to cervical cancer. HPV causes virtually
all cancer of the cervix and is the most common sexually
transmitted disease [17]. The setting for this example is a
screen-treat strategy in low- and middle-income countries,
in which treatment is provided to all with a positive
screening test.
We used this example in prior GRADE articles [2,3,5].
It is based on a systematic review of five studies assessing
the accuracy of HPV and VIA against a common reference
standard (a combination colposcopy with or without bi-
opsy and in some instances clinical follow-up as well)
[16]. For the HPV test, the pooled sensitivity was 95%
(95% CI: 84 to 98) and the pooled specificity 84% (95%
CI: 72 to 91), and for VIA, the pooled sensitivity was
69% (95% CI: 54e81) and the pooled specificity 87%
(95% CI: 79 to 92). The diagnostic sensitivity is 26%
points higher with HPV compared with VIA (95% CI:
11% to 41% higher), whereas the specificity is 3% lower
(95% CI: 15% lower to 8% higher) (Method in
Appendix 1). At the estimated prevalence in the general
population of 2%, based on WHO data [17], if 1,000
women are screened with the HPV test instead of VIA,
five more true positives will be found (2 to 8 more),
although there will be 34 more FPs (147 more to 78
fewer), who would receive treatment.
No serious concerns regarding risk of bias, indirectness,
or publication bias for this comparison of test accuracy
were identified. Whether there are serious problems with
inconsistency (the estimated differences in sensitivity with
HPV vs. VIA in the included five studies ranged from an
increase of 1% to an increase in 56%, and the estimated dif-
ference in specificity ranged from a decrease of 22% to an
increase in 9%) and imprecision will depend on the ranges
used; those judgments are described in the following.7.1. Noncontextualized approaches (primarily for
systematic reviews or health technology assessments)
7.1.1. Using the ranges of the confidence intervals
The first noncontextualized approach listed in Table 1 is
to assess our certainty in the ranges defined by the 95% CIs.
In this case, we would be rating how certain we are that the
sensitivity of the HPV test is 11% to 41% higher than VIA
and the specificity is somewhere between 15% lower and
8% higher. Because the estimated difference of the test ac-
curacy results in individual studies are outside of these
ranges, we might rate down for inconsistency in both sensi-
tivity and specificity. With this approach, we do not judgethe width of the intervals, that is, precision is omitted from
the ratings, and because no serious concerns were identified
for the other domains, we would end up with moderate rat-
ings of certainty for the ranges set by the 95% CIs
(Table 2). Different target audiences can use these ranges
with certainty ratings for their particular goals, for example,
as input into a model for estimating downstream
consequences.
7.1.2. Using the direction of effect
The second noncontextualized approach for defining
ranges is to use the boundary of no difference in sensitivity
or specificity. When doing so, we are addressing our cer-
tainty in the direction (increase or decrease) of sensitivity
and specificity, neglecting the magnitude of the difference.
In this case, we would be rating how certain we are that by
using the HPV test rather than VIA, we would increase the
sensitivity and decrease the specificity. Because the entire
CI for the difference in sensitivity lies on one side of no ef-
fect, as well as the estimated differences in all the included
studies, we would not rate down for imprecision or incon-
sistency and we would have high certainty that the HPV test
indeed increases the sensitivity for detecting CIN 2-3. On
the other hand, there is a serious problem with imprecision
for specificity because the CI reaches from a decrease of
15% to an increase of 8%. Furthermore, individual studies
have estimated differences in specificity between an in-
crease in 9% and a decrease in 22%, and we would there-
fore rate down for both imprecision and inconsistency
(Table 2).
7.1.3. Partly contextualized ratings of certainty: ranges
of magnitude of accuracy (primarily for systematic re-
views and health technology assessments)
Using this approach, one would define ranges for a triv-
ial, small, moderate, or large difference in sensitivity and
specificity. Because these judgments are based on the
downstream health consequences, reviewers must address
these clearly in the beginning of the review process. In
our example, a simple model was used based on five out-
comes: cervical cancer, cervical cancer-related mortality,
major bleeds, premature delivery, and major infections
(Fig. 1; detailed explanation in Appendix 1). Cervical can-
cer and cervical cancer-related mortality due to FN test re-
sults could be reduced using a test with a higher sensitivity.
Major bleeds, premature delivery, and major infections due
to FP test results can be reduced using a test with a higher
specificity.
The model provides approximations regarding how dif-
ferences in sensitivity and specificity will affect the out-
comes of interest. At a prevalence of 2% [17], increasing
sensitivity by 1% would result in approximately two fewer
cervical cancer-related deaths and three fewer cases of cer-
vical cancer per million women screened. A 1% increase in
specificity will result in approximately three fewer major
bleeds, six fewer premature births, and 1 less major
Table 2. Examples of certainty ratings for the difference in sensitivity and specificity between HPV and VIA
Approaches Examples of set ranges Certainty
Range: 95% confidence interval Sensitivity: The 95% CI, in this case, an
increase by 11e41% (at a pretest
probability of 2%, 2e8 more true
positives per 1,000 women screened.)
Specificity: The 95% CI, in this case, a
decrease by 15% to increase by 8% (at
a pretest probability of 2%, 147 more
to 78 fewer false positives per 1,000
women screened)
We have moderate certainty that the true
increase in sensitivity is between 11%
and 41% (rating down for
inconsistency)
We have moderate certainty that the true
difference in specificity is between a
15% decrease and an 8% increase
(rating down for inconsistency)
rsens s 1, rspec s 1 Direction of effect We have high certainty that the sensitivity
of HPV testing is higher than VIA for
detecting CIN 2-3
We have low certainty that the specificity
of HPV testing is lower than VIA for
detecting CIN 2-3 (rating down for
imprecision and inconsistency)
Specified magnitude of difference in
sensitivity and specificity
The set range for a large effect on
sensitivity was a difference in more
than four true positives per 1,000
screened (corresponds to mortality of
more than 50 and cervical cancer cases
of more than 60, per million screened)
The set range for a no or trivial difference
in specificity was a difference in up to
200 false positives per 1,000 screened
(corresponds to a difference of up to
approximately 33 major bleeds, 120
premature births, and 13 major
infections per million women screened)
We have low certainty that HPV has a
large increase in sensitivity compared
with VIA (rating down for imprecision
and inconsistency)
We have low certainty that there is no or
trivial difference in specificity between
HPV and VIA (rating down for
imprecision and inconsistency)
Range determined with considerations of
all critical direct and downstream
health outcomes or all desirable and
undesirable consequences
Thresholds based on the values we place
on mortality and cervical cancer vs.
major bleeds, premature delivery, and
major infections.
Considering downstream health
outcomes, we have low certainty in the
sensitivity outcome, that is, this
outcome may not shift the overall
balance between net benefit and net
harm (rating down for imprecision and
inconsistency).
Considering downstream health
outcomes, we have low certainty in the
specificity outcome, that is, this
outcome may not shift the overall
balance between net benefit and net
harm (rating down for imprecision and
inconsistency).
Abbreviations: CI, confidence interval; CIN, Cervical intraepithelial neoplasia; HPV, human papillomavirus; VIA, visual inspection of the cervix
with acetic acid.
The partially and fully contextualized ranges are set considering a prevalence of 2%.
7M. Hultcrantz et al. / Journal of Clinical Epidemiology - (2019) -infection per million women screened. One can use this in-
formation to guide the choice of ranges for no or trivial,
small, moderate, or large difference in sensitivity or speci-
ficity. As previously noted, the choices of ranges will likely
differ depending on the value placed on the outcomes. In
contrast to a range set directly on a patient-important
outcome, the ranges for sensitivity and specificity can be
affected by several downstream health outcomes. This is
illustrated in Table 3, in which examples of ranges for the
difference in sensitivity and specificity for HPV vs. VIA
are presented.For this example, the point estimate for sensitivity was
within the presented range of a large increase. As the CI
crosses the border of a moderate increase, and individual
studies have estimated differences that can be considered
trivial or small, the certainty rating is low because of impre-
cision and inconsistency. For specificity, the point estimate
is within the range defined as a no or trivial difference.
Because the CI crosses the border to a small decrease,
one would rate down for imprecision. In addition, one of
the included studies has an estimated decrease of 22% in
specificity (considered a medium-large difference), which
Fig. 1. Estimated consequences of the four possible test results for CIN. The setting for this example is a screen-treat strategy in low- and middle-
income countries, in which treatment is provided to all with a positive screening test.
8 M. Hultcrantz et al. / Journal of Clinical Epidemiology - (2019) -might warrant rating down for inconsistency, in which case,
the certainty rating would be low (Table 2).7.1.4. Fully contextualized ratings (primarily for
guidelines or other decisions) of test accuracy
When making fully contextualized ratings of the differ-
ence in sensitivity and specificity, we start by considering
the downstream health outcomes (Fig. 1). Moreover, just
as for treatment interventions, we will have to specify
values for all critical health outcomes. The values should
be those of the patients, and the process for obtaining them
can include a systematic review of the relevant literature,
the experience of the topic experts in conducting shared
decision-making, consultation with patients and patient
groups, and conduct of targeted surveys [18e20].Table 3. Example of ranges set for different magnitudes of difference in sen
Sensitivity
No or trivial difference in sensitivity: 0e4%
Difference in 0e1 TP found per 1,000 screened (corresponds to a
difference in mortality of up to 10 and cervical cancer cases of
up to 12, per million women screened)
Small difference in sensitivity: 4e10%
Difference in 1e2 TP per 1,000 screened (corresponds to a
difference in mortality of around 10e25 and cervical cancer
cases of around 12e30, per million women screened)
Moderate difference in sensitivity: 10e20%
Difference in 2e4 TP per 1,000 screened (corresponds to a
difference in mortality of around 25e50 and cervical cancer
cases of around 30e60, per million women screened)
Large difference in sensitivity: more than 20%
More than 4 TP per 1,000 screened (corresponds to mortality of
more than 50 and cervical cancer cases of more than 60, per
million screened)
Abbreviations: FP, false positives; HPV, human papillomavirus; TP, true
The boundaries of the ranges represent a hypothetical group consensus b
related mortality (for sensitivity), and major bleeds, premature births, and
a The values for sensitivity and specificity represent the absolute rangeIn the present example, the guideline panel might infer
that women eligible for screening would value major in-
fections and major bleeds equally, premature delivery
twice as high, and would place an appreciably greater
value on cervical cancer and cervical cancer-related
mortality, say seven and 20 times higher, respectively.
Such an inference may be informed by, for example, re-
ported utility estimates from similar clinical contexts
[21e23].
The question will be how much harm we are willing to
accept, given a certain benefit, or the other way around. For
this particular example, the guideline panel will consider
how certain they are that the increase in sensitivity is high
enough to outweigh the potential decrease in specificity. At
a prevalence of 2%, the estimated effect of increasing sensi-
tivity with 1% is 2.5 fewer cervical cancer-related deathssitivity and specificity for HPV vs. VIAa
Specificity
No or trivial difference in specificity: 0e10%
Difference in 0e100 FP per 1,000 screened (corresponds to a
difference of up to approximately 33 major bleeds, 60 premature
births, and 13 major infections per million women screened)
Small difference in specificity: 10e20%
Difference in 100e200 FP per 1,000 screened (corresponds to a
difference of approximately 33e66 major bleeds, 60e120
premature births, and 13e26 major infections per million
women screened)
Moderate difference in specificity: 20e30%
Difference in 200e300 FP per 1,000 screened (corresponds to a
difference of approximately 66e100 major bleeds, 120e180
premature births, and 26e39 major infections per million
women screened)
Large difference in specificity: more than 30%
More than 300 FP per 1,000 screened (corresponds to a difference
of approximately 100 or more major bleeds, 180 or more
premature births, 39 or more major infections per million women
screened)
positives; VIA, visual inspection of the cervix with acetic acid.
ased on the importance placed on cervical cancer and cervical cancer-
major infections (for specificity).
s at a prevalence of 2%.
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screened. Correspondingly, the estimated effect of
increasing specificity with 1% would be six fewer prema-
ture deliveries, 1.3 fewer major infections, and 3.3 fewer
major bleeds per million women screened.
Using the estimated effects on downstream health out-
comes and the values suggested previously, the guideline
development group decided to accept a 4.5% decrease in
specificity for every percentage increase in sensitivity
(calculation in Appendix Table 1). This means that even
if the lower limit of the CI of sensitivity (11% increase)
were true, we would accept an increase in specificity of
50%. Because the entire CI of specificity is within this
range, one would not rate down for imprecision in the spec-
ificity outcome. For the same reason, we would not rate
down for imprecision in the sensitivity outcome. One
should, however, also consider the uncertainty of the esti-
mated downstream health outcomes on which we are
basing the chosen range. Is it, for example, possible that
the increased risk of premature delivery in treated women
is 0.4% instead of the estimated 0.06%? If this is plausible,
we would only accept an increase in specificity of 0.9% for
every percentage increase in sensitivity (calculation in
Appendix Table 2), and rating down for both imprecision
and inconsistency for sensitivity and specificity would be
warranted.
Just as for intervention effects, the fully contextualized
ratings represent a sensitivity analysis addressing whether
the test outcomes being considered (in this case sensitivity
and specificity) are influential in altering the overall net
benefit or harm.Fig. 2. The 17 items in the evidence to decision framework [2] and how the il
tualized approaches for setting ranges related to them.8. Certainty ratings in the evidence to decision
framework
As illustrated in Fig. 2 the ranges with different levels of
contextualization will take into account one or several of the
criteria in the evidence to decision framework [2]. For the
noncontextualized ranges, only test accuracy is considered,
whereas some level of consideration of the positive and
negative health outcomes and values of these will be needed
to set the partially contextualized ranges. For the fully
contextualized ranges, all direct and downstream health out-
comes are considered, as well as the balance of effects based
on patient values. Depending on the perspective taken in the
guideline, one could choose to also incorporate resource use,
as well as issues of equity, acceptability, and feasibility when
setting the fully contextualized ranges for sensitivity and
specificity. For example, from a policy makers’ perspective,
one might want to include resources, such as further expen-
sive testing in FPs or more expensive treatments due to de-
layed diagnosis in FNs.9. Discussion
This paper illustrates the concepts of certainty of evi-
dence applied to test accuracy. We show that defining
ranges for the certainty ratings is important because the
ranges chosen will affect the interpretation of the result
and the degree of certainty presented. More empirical data
are needed to inform approaches for defining ranges that
would be most useful and to what degree different levels
of modeling will affect the decisions being made.lustrated noncontextualized, partially contextualized, and fully contex-
10 M. Hultcrantz et al. / Journal of Clinical Epidemiology - (2019) -Situations also exist that are complicated by issues
related to research on tests. For example, primary research
on test accuracy is historically seldom performed with
direct comparisons between tests. Therefore, most often
systematic review authors, health technology assessors,
and guideline developers will not have access to primary
studies directly comparing the accuracy of the relevant test
strategies. Although this is starting to change, currently
many decisions will have to be made based on indirect
comparisons. Future studies are needed to inform how best
to deal with these specific challenges.
Modeling of downstream health outcomes will inevi-
tably include assumptions, which some review authors
might feel reluctant to make. However, making decisions
about tests will always require judgments regarding the
importance of outcomes, although guideline panels or deci-
sion makers may not make their judgments explicit. An
advantage of the fully contextualized approach for guide-
line development presented in this paper is the transparency
of all assumptions made.10. Conclusions
Previous work has shown that the certainty of evidence
is a rating of our certainty that the true effect lies in a
particular range. Although the examples related to interven-
tion effects, previous guidance suggested that review au-
thors specify the relevant thresholds underlying the
certainty judgments. This guidance also applies to ques-
tions of diagnosis. In this conceptual paper, we have illus-
trated what the suggested approaches for defining ranges
would mean when rating sensitivity and specificity in the
context of systematic reviews, health technology assess-
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